The discovery of this association in type 2 diabetes and glycaemic traits in humans highlights the potential for development of strategies to therapeutically enhance XBP1 expression in pancreatic beta-cells to reverse beta-cell decline and dysfunction. Here, XBP1 is linked to type 2 diabetes mellitus.